Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Propranolol responsiveness in vascular tumors is not determined by qualitative differences in adrenergic receptors.

Boucek RJ Jr, Kirsh AL, Majesky MW, Perkins JA.

Otolaryngol Head Neck Surg. 2013 Nov;149(5):772-6. doi: 10.1177/0194599813503445. Epub 2013 Sep 5.

PMID:
24009211
2.

[Comparative study on pathology of non involuting congenital hemangioma and infantile hemangioma].

Song J, Ouyang TX, Huang YY, Liu J, Xiao Y, Chen HP, Yu J.

Zhonghua Zheng Xing Wai Ke Za Zhi. 2011 May;27(3):178-81. Chinese.

PMID:
21837995
3.

Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy.

Chen XD, Ma G, Huang JL, Chen H, Jin YB, Ye XX, Hu XJ, Lin XX.

Pediatr Dermatol. 2013 Sep-Oct;30(5):549-53. doi: 10.1111/pde.12192. Epub 2013 Aug 5.

PMID:
23909679
4.

Oral propranolol: an effective, safe treatment for infantile hemangiomas.

Zaher H, Rasheed H, Hegazy RA, Hegazy RA, Abdelhalim DM, Gawdat HI.

Eur J Dermatol. 2011 Jul-Aug;21(4):558-63. doi: 10.1684/ejd.2011.1372.

PMID:
21697036
5.

Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas.

Phillips JD, Zhang H, Wei T, Richter GT.

JAMA Facial Plast Surg. 2017 Mar 1;19(2):102-107. doi: 10.1001/jamafacial.2016.1188.

PMID:
27737446
6.

Propranolol for treatment of ulcerated infantile hemangiomas.

Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, Bodak N, Hamel-Teillac D, Kupfer-Bessaguet I, Lacour JP, Naouri M, Vabres P, Hadj-Rabia S, Nguyen JM, Stalder JF, Barbarot S; Groupe de Recherche Clinique en Dermatologie Pédiatrique..

J Am Acad Dermatol. 2011 May;64(5):827-32. doi: 10.1016/j.jaad.2010.12.040. Epub 2011 Feb 25.

PMID:
21353332
7.

Congenital hemangiomas and infantile hemangioma: missing links.

Mulliken JB, Enjolras O.

J Am Acad Dermatol. 2004 Jun;50(6):875-82.

PMID:
15153887
8.

Propranolol targets the contractility of infantile haemangioma-derived pericytes.

Lee D, Boscolo E, Durham JT, Mulliken JB, Herman IM, Bischoff J.

Br J Dermatol. 2014 Nov;171(5):1129-37. doi: 10.1111/bjd.13048. Epub 2014 Aug 28.

9.

Immunohistochemical investigations of orbital infantile hemangiomas and adult encapsulated cavernous venous lesions (malformation versus hemangioma).

Osaki TH, Jakobiec FA, Mendoza PR, Lee Y, Fay AM.

Ophthal Plast Reconstr Surg. 2013 May-Jun;29(3):183-95. doi: 10.1097/IOP.0b013e31828b0f1f.

PMID:
23584448
10.

Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center.

Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT.

Laryngoscope. 2010 Apr;120(4):676-81. doi: 10.1002/lary.20807.

PMID:
20112413
11.

Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function.

Tan ST, Itinteang T, Leadbitter P.

Pediatrics. 2011 Mar;127(3):e772-6. doi: 10.1542/peds.2010-1703. Epub 2011 Feb 28.

PMID:
21357335
12.

Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor.

Ozeki M, Nozawa A, Hori T, Kanda K, Kimura T, Kawamoto N, Fukao T.

Pediatr Int. 2016 Nov;58(11):1130-1135. doi: 10.1111/ped.12981. Epub 2016 Jul 7.

PMID:
26991797
13.

[Hemangioma. New aspects of pathogenesis, differential diagnosis and therapy].

Höger PH.

Hautarzt. 2012 Feb;63(2):112-20. doi: 10.1007/s00105-011-2312-9. German.

PMID:
22349036
14.

Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas.

Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D.

JAMA Otolaryngol Head Neck Surg. 2013 Oct;139(10):1026-31. doi: 10.1001/jamaoto.2013.4773.

PMID:
24135743
15.

Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions.

Hermans DJ, Bauland CG, Zweegers J, van Beynum IM, van der Vleuten CJ.

Br J Dermatol. 2013 Apr;168(4):837-43. doi: 10.1111/bjd.12189.

PMID:
23278381
16.

Update on infantile hemangiomas.

Lee KC, Bercovitch L.

Semin Perinatol. 2013 Feb;37(1):49-58. doi: 10.1053/j.semperi.2012.11.003. Review.

PMID:
23419763
17.

Beta-blockers for childhood vascular tumors.

Bayart CB, Brandling-Bennett HA.

Curr Opin Pediatr. 2015 Aug;27(4):454-9. doi: 10.1097/MOP.0000000000000238. Review.

PMID:
26087423
18.

Rapidly involuting congenital hemangioma: clinical and histopathologic features.

Berenguer B, Mulliken JB, Enjolras O, Boon LM, Wassef M, Josset P, Burrows PE, Perez-Atayde AR, Kozakewich HP.

Pediatr Dev Pathol. 2003 Nov-Dec;6(6):495-510.

PMID:
15018449
19.

Propranolol for infantile hemangiomas.

Bagazgoitia L, Torrelo A, Gutiérrez JC, Hernández-Martín A, Luna P, Gutiérrez M, Baño A, Tamariz A, Larralde M, Alvarez R, Pardo N, Baselga E.

Pediatr Dermatol. 2011 Mar-Apr;28(2):108-14. doi: 10.1111/j.1525-1470.2011.01345.x. Epub 2011 Mar 8.

PMID:
21385205
20.

Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas.

Schiestl C, Neuhaus K, Zoller S, Subotic U, Forster-Kuebler I, Michels R, Balmer C, Weibel L.

Eur J Pediatr. 2011 Apr;170(4):493-501. doi: 10.1007/s00431-010-1324-2. Epub 2010 Oct 9.

PMID:
20936416

Supplemental Content

Support Center